Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

26 Apr 2011

Abstract excerpt

Persistent STAT3 signaling contributes to malignant progression in many diverse types of human cancer. STAT3 is constitutively active in activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL), a class of nongerminal center derived DLBCL cells for which existing therapy is weakly effective. In this report, we provide a preclinical proof of concept that STAT3 is an effective molecular target for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21521803
DOI: 10.1158/0008-5472.can-10-2380

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell LymphomaPMID 21521803Read ↗

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.Semantic proximity Read ↗

STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

STAT3 Activation and Oncogenesis in LymphomaSemantic proximity Read ↗

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsSemantic proximity Read ↗

STAT3 SIGNALING: Anticancer Strategies and ChallengesSemantic proximity Read ↗

STAT3 Inhibitors: Finding a Home in Lymphoma and LeukemiaSemantic proximity Read ↗

Novel activators and small-molecule inhibitors of STAT3 in cancerSemantic proximity Read ↗

Critical analysis of the potential for targeting STAT3 in human malignancySemantic proximity Read ↗

STAT proteins as novel targets for cancer drug discoverySemantic proximity Read ↗

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancersSemantic proximity Read ↗

The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.